MARKET

FMTX

FMTX

Forma Therapeutics Holdings, Inc.,
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.54
-0.80
-1.80%
Closed 16:00 07/10 EDT
OPEN
44.35
PREV CLOSE
44.34
HIGH
46.74
LOW
43.13
VOLUME
571.20K
TURNOVER
--
52 WEEK HIGH
50.00
52 WEEK LOW
37.50
MARKET CAP
1.60B
P/E (TTM)
-31.2003
1D
5D
1M
3M
1Y
5Y

FMTX News

More
The Week Ahead In Biotech: J&J Kickstarts Pharma Earnings, Repare Therapeutics IPO
Biotech stocks advanced in the week ended July 10 amid mixed news flow emerging out of the sector.
Benzinga · 10h ago
Leaf Group, Forma Therapeutics See Activist Action
Oak Investment Partners disclosed a large stake in digital-content provider Leaf Group. Forma Therapeutics said it owns more than nine million shares of biopharmaceutical firm Forma.
Barrons.com · 07/02 23:30
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 06/26 12:28
Forma Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Forma Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Business Wire · 06/23 20:05
Shares of Forma Therapeutics Open For Trade At $40; IPO Priced At $20 Per Share
Benzinga · 06/19 14:37
Forma Therapeutics Shares To Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m.; IPO Priced At $20/Share
Benzinga · 06/19 14:02
Forma Therapeutics Prices 13.8M Share IPO @$20/Share
Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) announced the pricing of its initial public offering of 13,882,352 shares of common stock at a public offering price of $20.00 per share. All of the shares are being offered by Forma.
Benzinga · 06/19 09:38
Forma Therapeutics Announces Pricing of Initial Public Offering
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the pricing of its initial public offering of 13,882,352 shares of common stock at a public offering
Business Wire · 06/19 01:04

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About FMTX

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with rare hematologic diseases and cancers. Its pipeline consists of seven product candidates, two of which it is pursuing as core product candidates for development: FT-4202 for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Its other product candidate includes FT-2102 (Olutasidenib), FT-8225, FT-4101, CC-95775 and BI-1701963. FT-4202 is an oral, once-daily, potentially disease-modifying therapy. FT-4202 is a potent activator of pyruvate kinase-R (PKR), designed to improve RBC metabolism, function and survival, and potentially resulting in both increased hemoglobin levels and reduced VOCs. FT-7051, is a potent and selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300).
More

Webull offers kinds of Forma Therapeutics Holdings Inc stock information, including NASDAQ:FMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FMTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FMTX stock methods without spending real money on the virtual paper trading platform.